Advanced Lung Carcinoma Recruiting Phase 1 / 2 Trials for Osimertinib (DB09330)

IndicationStatusPhase
DBCOND0114971 (Advanced Lung Carcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03831932Glutaminase Inhibitor CB-839 Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung CancerTreatment